Valion Bio宣布1比25缩股以恢复纳斯达克最低股价合规

----- 0001683168-26-006742.txt -----
0001683168-26-006742.txt : 20260827
0001683168-26-006742.hdr.sgml : 20260827
20260827083016
ACCESSION NUMBER: 0001683168-26-006742
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 13
CONFORMED PERIOD OF REPORT: 20260826
ITEM INFORMATION: Material Modifications to Rights of Security Holders
ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION: Regulation FD Disclosure
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260827
DATE AS OF CHANGE: 20260827
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Valion Bio, Inc.
CENTRAL INDEX KEY: 0001787740
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
EIN: 814016391
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41052
FILM NUMBER: 261325284
BUSINESS ADDRESS:
STREET 1: 1305 E. HOUSTON STREET
STREET 2: BUILDING 1, SUITE 311
CITY: SAN ANTONIO
STATE: TX
ZIP: 78205
BUSINESS PHONE: (888)276-6888
MAIL ADDRESS:
STREET 1: 1305 E. HOUSTON STREET
STREET 2: BUILDING 1, SUITE 311
CITY: SAN ANTONIO
STATE: TX
ZIP: 78205
FORMER COMPANY:
FORMER CONFORMED NAME: Tivic Health Systems, Inc.
DATE OF NAME CHANGE: 20190910
8-K
1
valion_8k.htm
CURRENT REPORT
Tivic Health Systems, Inc. Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date
of earliest event reported):
August 26,
2026
Valion
Bio, Inc.
(Exact name of Registrant as Specified in Its
Charter)
Delaware
001-41052
81-4016391
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1305 E. Houston Street,
Building 1, Suite 311
San Antonio
,
Texas
78205
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code:
888
276-6888
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
VBIO
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
☐
Item 3.03 Material Modification to Rights of Security Holders.
To the extent required by Item 3.03 of Form 8-K,
the information contained in Item 5.03 of this Current Report on Form 8-K (this “Current Report”) is incorporated by reference
herein.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.
The Board of Directors of Valion Bio, Inc., a
Delaware corporation (the “Company”), has approved a reverse stock split of the Company’s issued and outstanding shares
of common stock, par value $0.0001 per share (“Common Stock”), at a ratio of 1-for-25 (the “Reverse Split”). The
Company anticipates that the Reverse Split will become effective on August 31, 2026 (the “Effective Date”).
Reason for the Reverse Split
The Company is effecting the Reverse Split in
order to regain compliance with the $1.00 minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2), for continued
listing on The Nasdaq Capital Market (the “Minimum Bid Price Requirement”).
As previously disclosed in that Current Report
on Form 8-K filed by the Company with the Securities and Exchange Commission (the “Commission”) on March 20, 2026, the Company
received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on March
19, 2026, notifying the Company that, because the closing bid price of the Company’s Common Stock was below $1.00 per share for
30 consecutive trading days, the Company was not currently in compliance with the Minimum Bid Price Requirement. In accordance with Listing
Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until September 15, 2026, to regain compliance with the Rule.
By effecting the Reverse Split, the Company expects
that the closing bid price of the Common Stock will increase above the $1.00 per share requirement to regain compliance with the Minimum
Bid Price Requirement. Although no assurances can be provided, the Company believes that the Reverse Split will enable the Company to
maintain its Nasdaq listing.
Effects of the Reverse Split
Effective Date; Symbol; CUSIP Number.
The Reverse Split will become effective as of
12:01 a.m. Eastern Time on the Effective Date, and the Common Stock will begin trading on a split-adjusted basis at the open of business
on the Effective Date. In connection with the Reverse Split, the CUSIP number for the Common Stock will change to 918942202. The trading
symbol for the Company, “VBIO,” will remain unchanged.
Split Adjustment; Treatment of Fractional Shares.
On the Effective Date, the total number of issued
and outstanding shares of Common Stock held by each stockholder of the Company will be converted automatically into the number of shares
of Common Stock equal to the number of issued and outstanding shares of Common Stock held by each such stockholder immediately prior to
the Reverse Split divided by twenty-five (25). No fractional shares will be issued in connection with the Reverse Split and no cash or
other consideration will be paid in connection with any fractional shares that would otherwise have resulted from the Reverse Split. Instead,
any fractional shares of Common Stock resulting from the Reverse Split will be rounded up to the nearest whole share of Common Stock.
2
Also on the Effective Date, all preferred stock,
options, warrants and other convertible securities of the Company outstanding, as well as the number of shares reserved under the Company’s
amended and restated 2021 equity incentive plan, as amended, in each case immediately prior to the Reverse Split, will be adjusted by
dividing the number of shares of Common Stock into which such shares of preferred stock, options, warrants and other convertible securities
are exercisable or convertible by twenty-five (25) and multiplying the exercise or conversion price thereof by twenty-five (25), all in
accordance with the terms of the plans, agreements or arrangements governing such securities and subject to rounding.
Certificated and Non-Certificated Shares.
Odyssey Transfer and Trust Company, the Company’s
transfer agent, is acting as exchange agent for the Reverse Split. Registered stockholders who hold shares of Common Stock are not required
to take any action to receive post-Reverse Split shares. Stockholders owning shares of Common Stock via a broker, bank, trust or other
nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to such broker’s particular processes,
and will not be required to take any action in connection with the Reverse Split.
Delaware
State
Filing.
On August
26, 2026, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Charter
Amendment”), with the Secretary of State of the State of Delaware, pursuant to which, effective August 31, 2026, the Reverse Split
will be effected. A copy of the Charter Amendment is attached to this Current Report as Exhibit 3.1 and is incorporated herein by reference.
Capitalization.
As a result
of the Reverse Split, each twenty-five (25) issued and outstanding shares of Common Stock will be combined into one (1) share of Common
Stock. The number of shares of Company Common Stock and preferred stock authorized for issuance under the Company’s Amended
and Restated Certificate of Incorporation, as amended, will remain unchanged. The Reverse Split will not change the par value of the Company’s
Common Stock or preferred stock.
Immediately after the Reverse Split, each stockholder’s
percentage ownership interest in the Company and proportional voting power will remain materially unchanged, except for changes and adjustments
that result from rounding fractional shares into whole shares. The rights and privileges of the holders of shares of Common Stock will
be substantially unaffected by the Reverse Split.
The above description of the Charter Amendment
and the Reverse Split is qualified in its entirety by reference to the Certificate of Amendment, a copy of which is attached to this Current
Report as Exhibit 3.1 and is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On August 27, 2026, the Company issued a
press release announcing the Reverse Split. A copy of that press release is furnished as Exhibit 99.1 to this Current Report and is
incorporated herein by reference.
The information set forth under Item 7.01 of this
Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into
any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any
incorporation
by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will
not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by
Regulation FD.
3
Forward-Looking
Statements
This Current
Report, including Exhibit 99.1 attached hereto, contains certain forward-looking statements that involve substantial risks and uncertainties.
Forward-looking statements may include, but are not limited to, statements related to the effectiveness of the Certificate of Amendment,
the Reverse Split and trading on Nasdaq on a post-reverse split adjusted basis, the effects of the Reverse Split (including on th
e
stock price of the Company’s Common Stock and dilution that may result from the rounding up of fractional shares in connection with
the Reverse Split), the Company’s ability to regain compliance with Nasdaq’s Minimum Bid Price Requirement, the Company’s
ability to maintain the listing of its Common Stock on Nasdaq, as well as statements, other than historical facts, that address activities,
events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future. When used
herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will”
and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.
Forward-looking statements in this Current Report,
including Exhibit 99.1 attached hereto, or hereafter, including in other publicly available documents filed with the Commission, reports
to the stockholders of the Company and other publicly available statements issued or released by us involve known and unknown risks, uncertainties
and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future
results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results
are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks
include, but are not limited to, the risks set forth herein and in other documents filed with the Commission, including in the Company’s
including most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, each of which could adversely affect the Company’s
business and the accuracy of the forward-looking statements contained herein.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
3.1
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Valion Bio, Inc., filed August 26, 2026
(effective August 31, 2026)
99.1
Press Release, dated August 27, 2026.
104
Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101)
4
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VALION BIO, INC.
Date:
August 27, 2026
By:
/s/ Melinda Lackey
Name: Melinda Lackey
Title: General Counsel and Senior Vice President of Legal Affairs
5
EX-3.1
2
valion_ex0301.htm
CERTIFICATE OF AMENDMENT
Exhibit 3.1
CERTIFICATE OF AMENDMENT
TO THE
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
VALION BIO, INC.
VALION BIO, INC. (the “
Corporation
”),
a corporation organized and existing under the General Corporation Law of the State of Delaware (the “
DGCL
”), hereby
certifies as follows:
1. The name of the Corporation
is Valion Bio, Inc. The Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware
on June 7, 2021, amended on August 31, 2021, amended and restated on November 12, 2021, amended on August 21, 2023, amended on March 7,
2025 and amended on April 28, 2026 (as amended and restated, the “
Certificate of Incorporation
”).
2. Section A of Article FOURTH
of the Certificate of Incorporation of the Corporation is hereby amended by adding the following paragraph to the end of Section A of
Article FOURTH:
“At the effective time
of this Certificate of Amendment, each twenty-five (25) issued and outstanding shares of Common Stock of the Corporation shall, automatically
and without any further action on the part of the Corporation or the holder thereof, be combined and converted into one (1) validly issued,
fully paid and non-assessable share of Common Stock of the Corporation, provided that in the event a stockholder would otherwise be entitled
to a fraction of a share of Common Stock of the Corporation pursuant to the provisions of this Section A of Article FOURTH, such stockholder
shall receive one whole share of Common Stock of the Corporation in lieu of such fractional share and no fractional shares shall be issued.”
3. This Certificate of Amendment
was duly adopted in accordance with the provisions of Section 242 of the DGCL by the directors and stockholders of the Corporation.
4. This Certificate of Amendment
shall become effective at 12:01 a.m. Eastern Time on August 31, 2026.
IN WITNESS WHEREOF, the undersigned
has executed this Certificate of Amendment this 26
th
day of August, 2026.
By:
VALION BIO, INC.
/s/ Lisa Wolf
Name: Lisa Wolf
Title: Chief Operating Officer
EX-99.1
3
valion_ex9901.htm
PRESS RELEASE
Exhibit 99.1
Valion Bio
Announces Reverse Stock Split
SAN ANTONIO, TX
– August 27,
2026
–
Valion Bio, Inc. (Nasdaq: VBIO) (“Valion Bio” or the “Company) announced today that its Board
of Directors has declared a 1-for-25 reverse stock split of the Company’s issued and outstanding shares of common stock. The
purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued
listing on the Nasdaq Capital Market (“Nasdaq”).
The reverse stock split was approved by the stockholders
of the Company at a special meeting of the Company held on August 14, 2026. The reverse stock split will become effective on August 31,
2026 (the “Effective Date”) at 12:01 AM Eastern Time. The Company’s common stock is expected to begin trading on a split-adjusted
basis when the markets open on August 31, 2026, under the current Nasdaq trading symbol “VBIO.”
The new CUSIP for the Company’s common stock
following the reverse split will be 918942202.
As a result of the reverse stock split, every
25 shares of the Company’s common stock issued and outstanding or held by the Company as treasury stock on the Effective Date will
be automatically reclassified into one new share of Company common stock. Proportionate adjustments will be made to the conversion and
exercise prices and the number of shares underlying the Company’s preferred stock, outstanding warrants, equity awards and options,
and the number of shares reserved under the Company’s amended and restated 2021 equity incentive plan, as amended.
The reverse stock split will not affect the number
of shares of preferred stock issued and outstanding, the number of shares of common stock or preferred stock authorized for issuance under
the Company’s charter or the par value of the Company’s common stock or preferred stock.
Each stockholder’s percentage ownership
interest in the Company and proportional voting power will remain materially unchanged, except for changes and adjustments that result
from rounding fractional shares into whole shares. The rights and privileges of the holders of shares of common stock will be substantially
unaffected by the reverse stock split. No fractional shares will be issued as a result of the reverse stock split. Any fractional shares
of common stock resulting from the reverse stock split will be rounded up to the nearest whole share and no stockholders will receive
cash in lieu of fractional shares. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s
percentage interest in the Company, except to the extent that the reverse stock split would result in a stockholder owning more common
shares as a result of the rounding up to the next whole share for each fractional share.
The Company’s transfer agent, Odyssey Transfer
and Trust Company (“Odyssey”), is acting as the exchange agent for the reverse stock split. Stockholders who hold their shares
in book-entry form or through a bank, broker, or other nominee do not need to take any action in connection with the reverse stock split.
Stockholders of record will be receiving information from Odyssey regarding their common stock ownership post-reverse stock split.
As previously announced, the Company received
a notification letter from the Listing Qualifications Department of Nasdaq on March 19, 2026, notifying the Company that, because the
closing bid price of the Company’s Common Stock was below $1.00 per share for 30 consecutive trading days, the Company was not currently
in compliance with the minimum bid price requirement. In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar
days, or until September 15, 2026, to regain compliance with the Rule. Although no guarantees can be offered, the Company believes that
this reverse stock split will allow it to regain compliance with the Nasdaq continued listing requirements and will enable the Company
to maintain its Nasdaq listing.
Additional information about the reverse stock
split and Valion can be accessed and viewed at the SEC’s website, www.sec.gov, and at the Company’s website, www.valionbio.com.
1
About Valion Bio, Inc.
Valion Bio, Inc. (Nasdaq: VBIO) is developing
biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease
and immune dysregulation.
The Company’s lead candidate, Entolimod,
is being developed as a potential medical countermeasure for Acute Radiation Syndrome and has been evaluated in animal models under the
U.S. Food and Drug Administration’s (“FDA”) Animal Rule, which allows the Agency to approve new drugs and biological
products based on animal efficacy studies when human clinical trials are not ethical or feasible, such as in the case of acute radiation
exposure. Entolimod is a novel Toll-like Receptor 5 agonist designed to activate NF-κB signaling pathways associated with cellular
protection, tissue recovery and immune response. The product candidate has received Fast Track and Orphan Drug designations from the FDA.
Valion Bio is also advancing Entolasta, a next-generation
TLR5 agonist designed for potential use in broader therapeutic applications, including oncology supportive care. The Company’s pipeline
includes potential programs in neutropenia and immune dysfunction.
Valion Bio’s wholly owned subsidiary, Velocity
Bioworks®, is a biologics contract development and manufacturing organization providing development and manufacturing services to
third-party biotechnology companies. Valion Bio also uses Velocity Bioworks to support its internal pipeline, with the objective of increasing
manufacturing control, reducing costs, accelerating development timelines and strengthening domestic supply-chain security.
For more information, visit www.valionbio.com.
Forward-Looking Statements
This press release may contain "forward-looking
statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained
in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by
the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,”
“expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,”
“predict,” “project,” “target,” “aim,” “should,” “will” “would,”
or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking
statements are based on Valion Bio’s current expectations and are subject to inherent uncertainties, risks, and assumptions that
are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove
to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors,
including, without limitation: Nasdaq’s grant of additional time to regain compliance with the minimum bid price requirement; the
effectiveness of the reverse stock split; the number of shares of the Company’s common stock that will be issued as a result of
rounding up fractional shares resulting from the reverse stock split to the nearest whole share, including dilution resulting from such
issuances; the price at which the Company’s common stock will trade after the reverse stock split is effected; the continued listing
of the Company’s common stock on the Nasdaq Capital Market; and the Company's financial condition. Given these risks and uncertainties,
you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause Valion Bio’s actual results to differ from those contained in the forward-looking
statements, see Valion Bio’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025,
filed with the SEC on March 30, 2026, under the heading "Risk Factors"; as well as the Company’s subsequent filings with
the SEC. Forward-looking statements contained in this press release are made as of this date, and Valion Bio undertakes no duty to update
such information except as required by applicable law.
Investor and Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@valionbio.com
2
EX-101.SCH
4
vbio-20260826.xsd
XBRL SCHEMA FILE
00000001 - Document - Cover
link:presentationLink
link:calculationLink
link:definitionLink
EX-101.LAB
5
vbio-20260826_lab.xml
XBRL LABEL FILE
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
EX-101.PRE
6
vbio-20260826_pre.xml
XBRL PRESENTATION FILE
XML
8
R1.htm
IDEA: XBRL DOCUMENT
Cover
Aug. 26, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 26, 2026
Current Fiscal Year End Date
--12-31
Entity File Number
001-41052
Entity Registrant Name
Valion
Bio, Inc.
Entity Central Index Key
0001787740
Entity Tax Identification Number
81-4016391
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
1305 E. Houston Street,
Entity Address, City or Town
San Antonio
Entity Address, State or Province
TX
Entity Address, Postal Zip Code
78205
City Area Code
888
Local Phone Number
276-6888
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.0001 per share
Trading Symbol
VBIO
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
false
XML
9
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
.report table.authRefData a {
display: block;
font-weight: bold;
}
.report table.authRefData p {
margin-top: 0px;
}
.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
.report table.authRefData .hide a:hover {
background-color: #2F4497;
}
.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
.report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
.report hr {
border: 1px solid #acf;
}
/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
.report td.pl div.a {
width: 200px;
}
.report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}
.report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}
.report .rou td {
border-bottom: 1px solid black;
}
.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}
/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
.report .nump {
padding-left: 2em;
}
.report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}
.report .text .big {
margin-bottom: 1em;
width: 17em;
}
.report .text .more {
display: none;
}
.report .text .note {
font-style: italic;
font-weight: bold;
}
.report .text .small {
width: 10em;
}
.report sup {
font-style: italic;
}
.report .outerFootnotes {
font-size: 1em;
}
XML
10
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
12
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.26.1
html
1
24
1
false
0
0
false
0
false
false
R1.htm
00000001 - Document - Cover
Sheet
http://VBIO/role/Cover
Cover
Cover
1
false
false
All Reports
Book
All Reports
valion_8k.htm
vbio-20260826.xsd
vbio-20260826_lab.xml
vbio-20260826_pre.xml
http://xbrl.sec.gov/dei/2026
true
false
JSON
14
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"valion_8k.htm": {
"nsprefix": "VBIO",
"nsuri": "http://VBIO/20260826",
"dts": {
"inline": {
"local": [
"valion_8k.htm"
]
},
"schema": {
"local": [
"vbio-20260826.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
"https://xbrl.sec.gov/country/2026/country-2026.xsd",
"https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
"https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
]
},
"labelLink": {
"local": [
"vbio-20260826_lab.xml"
]
},
"presentationLink": {
"local": [
"vbio-20260826_pre.xml"
]
}
},
"keyStandard": 24,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 3,
"http://xbrl.sec.gov/dei/2026": 3
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 59,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2026": 24
},
"report": {
"R1": {
"role": "http://VBIO/role/Cover",
"longName": "00000001 - Document - Cover",
"shortName": "Cover",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "AsOf2026-08-26",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"b",
"p",
"body",
"html"
],
"reportCount": 1,
"baseRef": "valion_8k.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "AsOf2026-08-26",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"b",
"p",
"body",
"html"
],
"reportCount": 1,
"baseRef": "valion_8k.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentDescription": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AmendmentDescription",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Description",
"documentation": "Description of changes contained within amended document."
}
}
},
"auth_ref": []
},
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AmendmentFlag",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_AnnualInformationForm": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AnnualInformationForm",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Annual Information Form",
"documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_AuditedAnnualFinancialStatements": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AuditedAnnualFinancialStatements",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Audited Annual Financial Statements",
"documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CityAreaCode",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CountryRegion": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CountryRegion",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Country Region",
"documentation": "Region code of country"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_CurrentFiscalYearEndDate": {
"xbrltype": "gMonthDayItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CurrentFiscalYearEndDate",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Current Fiscal Year End Date",
"documentation": "End date of current fiscal year in the format --MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentAccountingStandard": {
"xbrltype": "accountingStandardItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentAccountingStandard",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Accounting Standard",
"documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentAnnualReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentAnnualReport",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Annual Report",
"documentation": "Boolean flag that is true only for a form used as an annual report."
}
}
},
"auth_ref": [
"r11",
"r13",
"r14"
]
},
"dei_DocumentFiscalPeriodFocus": {
"xbrltype": "fiscalPeriodItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentFiscalPeriodFocus",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Period Focus",
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
}
}
},
"auth_ref": []
},
"dei_DocumentFiscalYearFocus": {
"xbrltype": "gYearItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentFiscalYearFocus",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Year Focus",
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodStartDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentPeriodStartDate",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period Start Date",
"documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
}
}
},
"auth_ref": []
},
"dei_DocumentQuarterlyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentQuarterlyReport",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Quarterly Report",
"documentation": "Boolean flag that is true only for a form used as an quarterly report."
}
}
},
"auth_ref": [
"r12"
]
},
"dei_DocumentRegistrationStatement": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentRegistrationStatement",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Registration Statement",
"documentation": "Boolean flag that is true only for a form used as a registration statement."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_DocumentShellCompanyEventDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentShellCompanyEventDate",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Shell Company Event Date",
"documentation": "Date of event requiring a shell company report."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentShellCompanyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentShellCompanyReport",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Shell Company Report",
"documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentTransitionReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentTransitionReport",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Transition Report",
"documentation": "Boolean flag that is true only for a form used as a transition report."
}
}
},
"auth_ref": [
"r15"
]
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentType",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_DocumentsIncorporatedByReferenceTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentsIncorporatedByReferenceTextBlock",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Documents Incorporated by Reference [Text Block]",
"documentation": "Documents incorporated by reference."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine2": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine2",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Two",
"documentation": "Address Line 2 such as Street or Suite number"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine3": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine3",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Three",
"documentation": "Address Line 3 such as an Office Park"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCountry": {
"xbrltype": "countryCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressCountry",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Country",
"documentation": "ISO 3166-1 alpha-2 country code."
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityBankruptcyProceedingsReportingCurrent": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityBankruptcyProceedingsReportingCurrent",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Bankruptcy Proceedings, Reporting Current",
"documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
}
}
},
"auth_ref": [
"r6"
]
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityCommonStockSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityCommonStockSharesOutstanding",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Common Stock, Shares Outstanding",
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
}
}
},
"auth_ref": []
},
"dei_EntityCurrentReportingStatus": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityCurrentReportingStatus",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": []
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityExTransitionPeriod": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityExTransitionPeriod",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Elected Not To Use the Extended Transition Period",
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
}
}
},
"auth_ref": [
"r19"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityFileNumber",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityFilerCategory": {
"xbrltype": "filerCategoryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityFilerCategory",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Filer Category",
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityInteractiveDataCurrent": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityInteractiveDataCurrent",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Interactive Data Current",
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
}
}
},
"auth_ref": [
"r16"
]
},
"dei_EntityPrimarySicNumber": {
"xbrltype": "sicNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityPrimarySicNumber",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Primary SIC Number",
"documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_EntityPublicFloat": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityPublicFloat",
"crdr": "credit",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Public Float",
"documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityRegistrantName",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityShellCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityShellCompany",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Shell Company",
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntitySmallBusiness": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntitySmallBusiness",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Small Business",
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityVoluntaryFilers": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityVoluntaryFilers",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Voluntary Filers",
"documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
}
}
},
"auth_ref": []
},
"dei_EntityWellKnownSeasonedIssuer": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityWellKnownSeasonedIssuer",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Well-known Seasoned Issuer",
"documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
}
}
},
"auth_ref": [
"r17"
]
},
"dei_Extension": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "Extension",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Extension",
"documentation": "Extension number for local phone number."
}
}
},
"auth_ref": []
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "LocalPhoneNumber",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_NoTradingSymbolFlag": {
"xbrltype": "trueItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "NoTradingSymbolFlag",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "No Trading Symbol Flag",
"documentation": "Boolean flag that is true only for a security having no trading symbol."
}
}
},
"auth_ref": []
},
"dei_OtherReportingStandardItemNumber": {
"xbrltype": "otherReportingStandardItemNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "OtherReportingStandardItemNumber",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Other Reporting Standard Item Number",
"documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r7"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r9"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "Security12bTitle",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_Security12gTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "Security12gTitle",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(g) Security",
"documentation": "Title of a 12(g) registered security."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SecurityExchangeName",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_SecurityReportingObligation": {
"xbrltype": "securityReportingObligationItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SecurityReportingObligation",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Security Reporting Obligation",
"documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
}
}
},
"auth_ref": [
"r10"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SolicitingMaterial",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r8"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "TradingSymbol",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "WrittenCommunications",
"presentation": [
"http://VBIO/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r18"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-23"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "g"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12, 13, 15d"
},
"r7": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r8": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r9": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r10": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "15",
"Subsection": "d"
},
"r11": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-K",
"Number": "249",
"Section": "310"
},
"r12": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-Q",
"Number": "240",
"Section": "308",
"Subsection": "a"
},
"r13": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Number": "249",
"Section": "220",
"Subsection": "f"
},
"r14": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Number": "249",
"Section": "240",
"Subsection": "f"
},
"r15": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Section": "13",
"Subsection": "a-1"
},
"r16": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-T",
"Number": "232",
"Section": "405"
},
"r17": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "405"
},
"r18": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
},
"r19": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "7A",
"Section": "B",
"Subsection": "2"
}
}
}
ZIP
15
0001683168-26-006742-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001683168-26-006742-xbrl.zip
M4$L#!!0 ( ,9C&UW],(E3'A\ !ZM - =F%L:6]N7SAK+FAT;>T]
M:UL:R=+?YU?TRSE[5I\%9 5->$\B)B0@;OO%IV$:F#C,D.E!)+_^K>K+
MW!@0C;HF)WEV$YWI2W5UW:NZY\5_;\8.N68^MSWWY9]FL?0G86[?LVQW^/+/
M1K?9;O_YW[KQ8A1 ,VCJ\I>Y41!,]K>V9K-9<58I>OYPR]S;V]NZP38YV6C_
M)K-=N50RMSZ_.^GV1VQ,"[;+ ^KV6=C)L=VKY>/CV[!ISW?L1%-\HB>I;"T,
M#6^MJ$.\\
M;QZD5*J8>
M9V%SDBO%USW*0XQ;+(5N/2>\@!X1?%->&%(Z"1L/*.^)8=6+=&/?
M))KWO:D;^/-L0-3+1 ?N!XM#P\-$HX^'[;.P%?XBWI9JT )9A5&K;A#\\R*P
M X?5+^QKNT]>,^H$(]*=\X"->9ZTW7Z1' /"2:WP]L66;&J\&+. $AR[P+Y-
M[>N7N:;G!LP-"A?S"2"W+W][F0O83; E6&X+>FW)65_\7Z% CFWF6/NDRX(#
M
MGK
M=Z_NA9WNT7M[[Y(!^0#0\%]CS%P+_@^.'3J\'%"'LSN,5(J-U)SZ/HYC\SYU
MOC#JMUSKB ;LTBQO5
YXU)SR8.^QE;@ $O$_,TB0@%_886IRR&>EX8^KFY8,\S._; V0ER[[6
MW2R;3QPZWR>NYS)\9]_L(\TS'WA-_&);%G.1\? W:'4Z'<,X?
YHYI/RCAGTJ.N+!HF(O9^PGJRM4%>;W82HS\(W-5XW,M
MH[]
AV ;'N9X_9XXC"49VJ:Q,AR*NY-?343-!+T
MMJ\6+Q::6KP2Q+HE$PO6#\/'MH4O!C;SB0"<92K+9OMM$C?ISN%D6UFSJ;DF
M@$C/6@ !S!4_P$VO1]#K<:)WZ5Y,$DI&'_TF!5)\=OU,H2^!TJEK2WP"5Z>1
M.&:43WU65]R_#TWT4/I58GP<*WMP*4B6C:\6+]K<
4.PI
MB)T&GA^]O?/:T^!EC!F;\8BYWMAV;YGS5GRD)\T85K^.+S^-1L5Z$:=)EE?"
M]L46]*T;1D)C=*8.*YS3H=# <;$]IO[0=@N!-P&9/P&UHA[TO"#PQNK9S+:"
M$>J$TA^Y1.^>Y\.
#935!=5/@]G?09?)%
MKOZ??YD[I0.Y#O5W;"E;B;7 ,B=WU5QZD3 C-"T=$.2N G7L(3SJ@U!@/BR3
M3Z@;'UD!B<-'(&(C@''R#\!113A>].H?3ML7K2/2O6A
CY(YVZK^:'3
MOFBWNJ1Q>D1:GYNO&Z>O6J1Y]NY=N]MMGYW*=B^V>G6]AMXM*_[4Z+YNG[ZZ
M.#O-DZ-BLTC*I>WJ7HB!WB-CX3;P4ANR%)S:G<&94 N=;4GD.\@.BP!&K32I
M[ZC=.3[KO",2=)1W:*7ME:096B@<>?TIFC#H.5SV0[L[LL"_?SL;LNZP,IW:
M-1CN?B:%68J;%/$Y
L*N843BB]?,
MVMQ?X%PSQ;GGPES3[F@F"WO;O%H[_OSM:#2\$PO+4,_+G'T3[%LP^AC:CBPZ
MGP.TS$VQN)G%X@G@
\KU.?N6?;J[
M
=Z8*Q6Z1WW/<>B$
M@RVK?Q+.\(M >84O BMA]\Z8/1S!?#W/ 0?JFOF!W:>.QOO8MBR'9
T'2519Y<"6NN?L0<.@.=N90U ^N1\%RN9N!Y.X'G8]MA %"/
M^=E(G
'VQPZO0]>;+N%_N?'CUMC.Z/[HR0K!+@ '"E!7,G
PLQX#CRX"__45@Z
M5]\0!(_6_AE8^3YY T8^MVSI!H :2##'YL-O)4#0],9CFV."FB!9$8F;QYFK
MW>F2UGCB>'-8:W)+R*E7W$RC6\^;/4EN'?BRX-#J9[T5/OH(C[_@2,
?#FYKC_:4(_[4J;\)[
?&W21[3%:DL7
MGH(Q5[]@-Y2GUTWN:& \#M6FD5[-0OJY!ZAP_K8GR^U?WCBO= [-YFG[ZOZT
MM+<4I0D(
X[(M!SVSN-^)H9?X\%$X
MX3__JI7-W0-.+IC#)B//U1:?B( X4Z&C&CZC NN+,53M *%PQ&;+.>KT"RL=
MC;P/-Q^_WINCRHGL1WQ.,-YKM24
8Z+7NF&?'T]H,U7;Z_<_OT!
M3\1TT_/FZN7=G<+.\A5(PR"+X)]?].5Q@CD/&\[Z"E:A/9CGZLT1ZU^)C J=
M@&:<^#;Z7SWOAO28X\V(+=,MNG"0#&P'&<+FQ,;*0(M91N 1;H^G3D!=!M:F
M,R<
JH/7@XFI=N/PA1]%]*8PCD^H.]?O!L#_W@S[H;:VT1GC^\]S
M@\3?Y6IQ.\REVBXZ
L>^=K>I[G,.J*HK045R=BRIE@(;KW=JO5@Z6<+?XQ
M5&< *MZ;3&+I0"R5(-7RMJ*79!I09/\VS%W2/.Z0
S"]
2D_=9SGZ$
YK:\1
M4UO:YGS*_%N)KF0>?O2Z0>T]O5M\?4VBVUY!= L0/A[I55BANM%?C_14VY^5
M]);Z>S$[0=J=S&=6 E=AK1&RGJ'L4,#/_J.GE']R=SM5%7LHJF+-J"0V/8AL
M&()4-9=[Z;*N\P*/*A%1V-0?D;Y#.0_=P30P*Y)S.$\V+"OC,C^X/'-G^?(N
M?"JB"]WYN.
)@NJL
MC9(#<[/<$V2UQ,:]ZK>^?N9G;'#_-'4YD:E)SPN.-XAMD9?Q^E=Y,J$^N:;.
ME)%_EXH8.243/!TR6C/1OVJGUT%/6:%'4:0DR&S
\H_X5"\C)27.M\/ES#9LM"4^U70LM&T9Z<](7H2KH=04R
MA(GR@%0
8$MAC,(AQX2(:^-PM&!AA($XPM44XL-K!=634F@PFE[<6"XE@=
M<85LX"IW#S!*7-D[$'$%W0=F@YV98-D9%BQ(8ZO<*Y0SAM2;:,1JE--CH_T5
M=8^-7GR>D:]
5D2T+6>[/77R;NAW?GO1^U
M[ -_FC;L,]):F; IFW[G%IO^>6[O,HX<9/"8WOD\<%8FP]KIF*\Q G8$@=H/
M@!U=3YC@4\Y$*YA61):)N"3 %F:Y/$F(^R/F
P>&^,-#1;U+2YCRE;,_C<29PTV:'C*(.XH%1^.K%M)LKZY
M"-
-%QJ?,>K:'8RBN#E<:S(55RCIG>ISY?R#1>.HJVV
MQI-"PF$#T2.=BJU4_DB6TRRVJ"[S)Q(7!4BT'A \[K5/&C[MV7U]=P"B_M0[
M(&<3$0C9)Z_%J7'< #5U_-BE'DN<(%T"4R4%DX_)^<6Z(&U3J:.J"YOM,WI5
MZ#%@0X!R(@ADO0U.554MG"V)3QA?6W2:] &I_%GR7Z_>#MB85(JE"M$I O+.
MLZ(J2HR"X;:)L@YM4I/7G@/
+>" 78[L]UG:]-JFA+X"*_EX$A(#11_#N,+A
QS.
M'3KC!Z0I[7P;JX?Q@@V"-VP\)*$M(8FGL/W0^3STP(9"#!P!R?4#SQ?HD >'
M2'AP*$^HH4\JD#BF-I 2-?5(HU&339Z@32C*$*Z!:"B:<\"D#-:"CBZ?.':@
M#;-85U&\8V,X'?JX -HT$*:>L/G$[048S>W+< N_-=R"7IF&+@S01"#2 '#
MM0@WK@ L52AO)Y;546!W$6#=LT@ >493NZ)@7F%]60 [$HQ@3.R>Z =:V7%(
MCP'
# 5JGUR)^I@X^5LP\$7
:)BNMYAE ,&T E8
M0!@8I(]W+NW)N4P3"DA2M?E S8M$8KN&L.M0.H%O!1)=>D
3\>D9X/G S8[TXH#!5P>PR.
<8D7K2IL>@2BKW058V=7TD)
M6_4X5-/0 C:F/P(Y(F5)/CZ3 >*=V5(2@X,>F50."\#2(@/?&XOVFD+>3V'M
M@S 1><1 R@8B10F2
(:YI\$3<,PU+VB4(![S*"NICB @CK%5
M1.I+]$9
I,,$^D$H'6C4D)RY[H<.%#)&XO.>3ZY0S ,1C3Z
PY4H6*((>%>$+WXIZ*50;DAEK9FFCO[E1V=QH;"Z"$$8YS!I 3AV&T0\%
M+K N1D4<(*()&#L]AK
);=D"1C;&$;!I.,/*FPQ'0(,AT/O6Q
M-P<*<(&X0ZI(K@VHWH:5KS9&F"L"#@G.\XPQ@(FN!+'!2%8
,L+99TM)7ILB%:!4BSPCDJGIT M
M! UM
%51W6;@W&G2#"]*(CR"3 TK/8X8WK]2\'!%D%XJ0J2N'MGX!
MNP\X1I).0VP>RN8#<@%:(#2)CGTJM@3L8WEIX"_"/6?9=(_/ @^] 45@@ +I
MMAO9;CLV2!#?B#G"'!8E)<*3'XDX7LJXT\R$5(\A:[1@IX&'D2\P@X0Y%LCX
M601(%"A(S AZ%>!=:+TRVG +V-,4[/9XS"P\= & @16!+.,9BQI8WJ HO8$9
M$-"\,$#4;I2W-XODU -K/"0F!8;&@@+67D,*B!6!V="G? 0VHN&))#M:O3"W
M"N#H82?4SAP4-V 1&&%7S+PI8$(,.K-ASA&]1KN'3QW
4Y\S$*%96OIX(X!AW+
?-K["B0K(B:HSQ\_ZO!$OD,3]TH$4Q5AGWIN(?'P
MU_(9K#GG;$Y$O=% ' :VX!=,=(7>8Q;K!V'[H4ABH'
G7W'(K* 7C%A 4LK50;R1!2=3#P>%)*6
MJ!RX*,?3TWHS=X4O<6U30DG/]Z[P@H(>=4$^! )-L#@A$@QQ"3MC4D8)$QL>
MVSX"8,O(?-(;"F68 ';@"'9:%'DQ3A.,*&$( ^D8Z[?[4X?Z&&+L,]A-GA>.
MG8 #$=5C4:5"!J[6<5!^#=X.$^.)@L(>V*%#(<304/3\?50/>-.MN'W&.!;G
MZ(MA@=VOP/7KK?],Y[P-S$XLY*E4FHR2F'1$O@EK-Y#8,#C=B)D)'6TFI#HE
MRCKBAD(RER9O&S7"*:+Z@'AZSF
2)%E2V3W?9W03Q*,3\!+IX/IS:XJ-K!
M (R1E1W)2U-[P?:\6SPM"N^->ZJ$+4 7!@8S-]-A&T-M@8S>B"CU$MM
MM#6.NG/D^>"BRUITA%R8MTN]$RUVC'N)G?R2^#A9DJ(0>6<5GD?S.JQS
MRLY_&XGU>GYZN;^ OFW'7#HZ"%B A?B"B'^)F P3$BIX^&&;0961/Q,TW
M(E!HNPE%).G%0^$I0Y37GC!%)]X,IHUOI+Z3 F *]S2/]BJ;2#M5/I,^#@T3
M""KY+#E,QC>UUY,1&54N9AC+Y))J?%D.*X$%G]5AP\A%#ZW0I8XK+L, [@-[
M$!DUT*N@2O7H>I5?S6Y#U,GLO<5XW[
S
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MVG*O/>
\"L_ KZ4&#Q2W'0?NA:!PO'VQ,YPI(EB>]:1#FCQQ[;,OT2S[>
M'HQS&FA?+E9TZBI[8Z5WF%% )AS2J+1456J+(E.1F@H/V\G6B8K3? R$[+IG
MLA%M@"@F4#3)#!DV6_\0!L)IV
T[N6*)J(
M2":O:@( :2X!'@D\'W47&0!NQ!;BV45UQSVBZUH8O7E#?"92)-XM^-'Q)C'J
M3SB>XL)GGM
8_
M?1^5&TK0)FH 4H5+4=U-QF3QM
11E)6,JGQ8^,J'I+XL%&02G3
Z]6!2U%
MT((SN4W&K7I
0VJ./"0M@^Z!4H
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M*B 0]0(<@, PDJR;Z[$1=0:ZW%#4
%D(:9\V%[RYNUJ368#=Y]F=YUV]
M4CQJNY]I\J_NES*X[S'"X7Q_Y3>K4\JYEU3.M^Z@7=_B6^0=
G
E]GZ\^#M^0WW&Z[?P_T>[O=POX=[OI\?
MV8Y]#N.$@K7X.P;SY#&8[:>,P3Q-2"2!A4 O^<:Z.2#M(_'#9:EV>"D^3R&*
MIP08HAM[
V=>C+Y\G
MO:'9WC$OSFOCK>#53KO=:799[:_3UMO7;4H_^G\?#8/YL'U6/NF:_>'0^3PY
MZKBGK5U^_6%\>+%W
_J]U/E )^:'T[G3G?U=GOSMF>>U5Z/VV<[5
M^-78&6SM?!GQT\[5X+CVZ6BK\>7O-S=ORN;;J]>UOMG\\.F]W3SG;SOOMDN]
M7=/_ZW/'N[;?
IXUQW]'P=BI_S]0
M2P,$% @ QF,;7?UIB*<_!0 TA< !$ !V86QI;VY?97@P,S Q+FAT
M;>58;6_B.!#^CL1_&"%MU4J4MVY[)YI%"I"VG%A20;JK_6@2A_@NQ)SME+*_
M_L9.TJ:%Z[927T[7JD"2L>?E>6;&CJT+[^NX5ZU8%XX]Q%_0?Y8W\L9.SVIF
MORAMYF*K[PY_P,S[,7:^U$*>J"ZT6RL%'EM2"1.ZABE?DJ2>/:C#C H6UG B
M3KTLYBEZHPY)S!9)%P1;1.H4ED0L&-ZV:CVKWW-N(C9G"HX:;:O91S\N'V@H
M#=]+YG)UNCWDJ
QI8)S1F"/1G"U)EY&/$0'H0_F@S
'Y8'S/ XBHH/--M>)3@?$Q
M1(=("'D<\[7LO@>6[\=BNP$>HI60)2T +>%
4H%)K,P,G_)HNYYA6[
UQNO-
M8:@G[G>.#Y BF>8UPU.%19,8=F2$+4!J#0.^7"(!,\7]OW9QC"/C& LW51@L
MTH-WV.:U/MUU4"?JWD"8"IPH@&1TXK_6@ZRK73IYM@I%/,X7)$%Y6(
&O:/,$6?T!C+IB4\.2124BG)
M')/)A/J$2.NP$OR:Z2Q6$5%H,R/B&A$% E)/RSU>\S1&/+7C:R:I=AP',86]
MN%I!3PF$HD BU'.?Z *L4B%3@O;R*C$>291(*!+@D3JN@TPQ!TJ>5BN&/FR7
M/M4IH2%
BZSS-'89$0U\M[[L:KZ2*_M
MC]1MM:*7\2"-=>/DJRS9L8RP\P8D\>G=VGX_%XHTZ'SN%*SI39ENP/HZ8$BY
MXD(:>DH9(7=P_,$6P\^_I*3(7.Q&Y4Z,3:'=Z;;:0!K+!CA$XNM"8IS:WC*=
M?#!01Q/X/O(FSFP&WR^
.>95LS\\XA<;YNC1&F.KVA?JI,DWV$@TS:.;%F
M5Y<]%5E-_0L!,1O;#.G_#LR>W1\[^$X^'L\N[<%H
97-7-,9'G3_+C(\H:W_GG#NX>%?;VB
MZE6\"%3QU:VIX\ZG6C'C9>$T!TOW@7L]*U;_UE!Q6/ _,=;?F$WQ;F9S$C^_
M((F_.()Y.1NO N&K:A[UFK()8R8)?.=Q:#5'O6UJRI6(7],GUNKS"SAO#WC=
MA7E,<"O71C\EQYTR^GKF3KQRQ(>2_:19V+7>!-_=NN5 ].CWB>-7KGIZB]V%
M0<1H".Z*ZNT+OLRX(:X@5#S#\Z9IV;T76#6V%H.F/I//#NGU6?X_4$L#!!0
M ( ,9C&UU+K021F0\ " ^ 1 =F%L:6]N7V5X.3DP,2YH=&WM6VUO
M&S<2_BY _X$77',)("F6\](D
C\]'%
MZ9NC)_Y?O'T27A\=OS_Y15R/?KDX_>[!Q.3E:]$_*$HQTG/EQ*5:BBLSEWG'
M/^B(:V7UY $^Q*
E^EAV9::G^6MA]716#L1
:46RCHEKDN3W(CK(M.E%Y;(W0?]
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ME84N92;>27NCREKU_FU0^^/>EW:HZ+I?ELMHC]Z7\ A9%-8L8-3QBM7#[V
R5-%@)&'_\/5!7PS?B5/ID")R5IAGO^W/
M37
2PPD20:^BM#(-SB.]O%V9DF+)L\;2X:/E3'G/FK,K(0X*/-B0
MGS70$54.K?+2I+*67#4X8^3B5O.QR>(6*2GTPL[NCR/F(/#VI^OS#QRGN[),
MTRKMUL1DF5G&U% [4--UQ*O^RU?/#J'D>Q*P0\0EMNJJK+PC;W8$/5LA.)XW
M4O"G-+HOB<,8'+HA#]0AC]QLE725787O0Q[=#$ V!2)""5F5V':I$YEE*XB-
M \
NC4Q';:+?51V41#77PZ.-XLK
J9F8)$=\A<>UGC/V4I\Z[3PC9[B1VGP5987DK*
M37#S?N2H<\)!9(0B(U>3]3?W)!+N/#1R@_.(W;"A83ZTUN&P9<$]WM_9;:(M
M1$,QLDT/[CXS%C YY7Q&Y!FKL%';K9W1".(E\?%&+Z05"YE5ZK.B][8(]\32
MIS*9-=''.@81RG!R.86"ECD\8::+=DL3_$=(")UOYJN<(&&=.S*Q,(Q2"K.$
MRMEM !,EOD*2@G2
Y
M5+F&A\PS[V_K9)117),;[G!DE$)K3][COK7_A5TC4 @FLL?MU9FILC2:2C-.
M73.GD"&MSXU5P2+M5K#X+A-'1VXJ_N.FUBDT% 7KMC+O22+:52@ H.=N0K:=
MPAX=\3Y=.:=68A2>^V-^9 GOQTP42\JP-I8H'2HT2''0,H$KMK)/-9YZC8MW
MQMOUAK//#"<+6JYM'7QP@K$Q-UT0 VHC1_5G#:P[G<'F8YD#RHRMN5&V0Z\,
MOK?P8-352HG4L#/C1RZ$2GFCV*>]M
.!@/SNRNXN&>Z'4PX9BRZTJ1PG
MG=#WZ6R
B]"2^0_%?C$54Z<*& 1/N3(5*$V
MQ>?OI$6X]U_%.I9I;V-F3E(=*N1E!1.4U/M),N-HV;I/LP?BO/5&]1U$:DN,
M%8H^\<]^[^" $ C]3P](/=S*JD8]\;2.94KMZD-(D-^'&IM.A_9=?]@.ZDG
MSI%3$W+;]5=1@5<5TN+SE_V#1\GC1T\?/QH^OBT#]5
7W783Z%8C4#R0(8BJW1TG(%7?0I>?$"8X2]UV$['KUM"D6Q^6*I?C3#6E
M@AQ&$"XKB07U, /)0.B^Q'&:ZG!F-C.>'*,8N9U&<52S)4AOH2D<# N'5$B/
MOI!9:+6D'SV%Z].W=5PMU=CI4G7$
$!;[@S$C0\6S'*L30\F
MOR<&^)O+'QYZ1/K_Z';%F599^EI\ %(9@,AOE4(: "_1[88!W=')^<]1$$^^
M6YKBM7A1U*.T[MB4I9F'9V-D5F7K9\>91 ;J0R!G,IV"_VAX?'$JWIY>7'P8
MGIR<7W[_W8.#!_S[]8?AV_A[8!FH)2;+9.$@6OQI@,R3EC/2R\$W ]$<;QWP
M>&MT%6D@ KE_%54!^3=UDZD)?W$2OPBDGS[]9FV5T
Y
_
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M,>Q/5)8A."SK) 0B"@WN'W*=3\,IT8BG&)"^YQ84N78\]HA8PHHS"3%'EK
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M7@69D"O2$)K1PJ:HK :3=9 YD$[\$T
V6,!_Q\KD=QX?*IV#(
M;?(4IY.C2" ILU4WF5$W@II-%ONX)]YXAG3 \X!&!Z(C%MI1S^?OLO_/07LH
MEVX!="^,N2&/NJ:A/7>_[@^\/SH'CM3
$7!+QO>9#Y*\_Q37.FB?K4W?@XI7:W)=HEYYLA3^0BM4Z88)2$
M$=:/*7- 3D ?1EF4-#I11.J2,\*ZM8_0:&Y*WJ!)('3?NS5ML9LTJ8A&K"D=
MAGPE9KSR=P0J#_*0)5-7(\ 9$D7B2X(F\?[H.%-Z.1N/R8QU+S(=GR1T+!P
M^R&EO'EC<;L57_!]N.WEE+7S6T2<4C?;S[#?6X^HX[#]D"^O;#^+D.&65- I
M2H[;1*SY=8>T)1Q:W7HJ]?S6!F:[=$/MZNU'S77M5IC6Y6HJXW&%WV%/;\QZ
MO.;T7 ,NTR5#<@J/L>2Z?>_'S/L]KPZN!O5;WMB,,?;DNDS9@4'B+41OY@"H
MN3F\&9$ZA_RT<",(.SXZ0SL9J'_N[SR%L0+12#45131?!I5@-HA<65((0M$3
MNVO/&UMH,I$,)B952<4F8J"^F$$Q1LKD0HZG"KY=7@$*T+P$P($2"X^]2:
5&)K
MW'FKI-UJWC>X?27E,R^-[+\ATJQA4IU5#(*WJ%*RI3Z'O[?E_(:]VDA^[A5\
M
FXC!,).M/I1Q>%-"9]!?=N-X/7D@2TO'U
MB1,4;I!JEU2
G7Z#G5#Q09,:XX*NGT9&/YD/93Z!U)3VXF
M .PC1/^^D"=%WH%D.B@/=C*::.J?N'5<7I^^;3ADARN@89Z3-%>*:R)0.*/;
M&OV#[H_U-9"5HD.#KT.=J,3/B,.=\N
$%U-H2&_2*N2^W=508MA'G+!YH U7*OB#A/G0KXA%_H=-(K.Y+)'
M?Z1S/Q#Z5RMWSO.%(H#-YGF' U["7V#BI+P_Y
P R@L !$ !V8FEO+3(P,C8P.#(V+GAS9+55VW+:,!!][TS_0?5K
MQC:0DB8$DFG2)L.4E!2:3/K4D>TU42-+CB1S^?M*OG$Q4*"MGZ3=<\[N2KMR
M^W(:430&(0EG':ONU"P$S.
LBV
M=Y!]!!9P\3#HEK+/2L6RY;J3R<1A?(PG7+Q(Q^?1;H)#A54B2[7:M)9_N]'O
MB/1+\M$7'O,/TP%Y&@$[33Y[3_%='T>]/KY7LV:S\?KC93J.!D
,,59
M&; UI82]K(/7S\[.W-1;0"O(J2=H(7WL&K>')93*VDNVX F3"C-_"1^HDK (
M;KJ9
W0^,9) 4RD/<(X+L$AEEXJFCN6P%*H
M*E ;5T&VFL4@UT(SUQ+A\:K;+[%FDWIKIP8!%")@ZH:+Z!.$.*$Z@=<$4Q(2
M""RDL!B!,LTE8^S#!I6B,S%C7#>P'J+<8FQQ3'2'E@9M,C?:$IS"=YTJ,@L]
M0
EI*3UMR/DY9#O7Q]1/Z$'4>7[;F+F].,#*R18#,X 0I8/6,BW1
ML20Q+YV5VYX%A!UK[!%N%_?X4Y?MZ)8I(";"ED%+[VCUI/+ A006?D6E\A!H
M$1Z#4$3W[<*T9ZD39>CW"V&0B2,MY/[#RBGV]JU<4X#^QY)[1K]::]M=GBB]
M7YVZMBZ7"X5896RWO9;9.]_C?BJUA6)V=L&SC
GE;U!+ P04 " #&8QM=6Z>:8OT* !_A@
M%0 '9B:6\M,C R-C X,C9?;&%B+GAM;,V=76_CN!6&[POT/W#=FQ88Q_G
M#I#L9!<93[(P-IMD8\]LVT6QH"7&$4*3 24G]K\O*8FR1/%(2HJ2G(L9C_@>
MZJ7XF*2^CC_]M%U3]$)$FG!V/CHZ.!PAPB(>)VQU/OHZ'U_,I[/9"*499C&F
MG)'S$>.CGW[\ZU^0_//IN_$8726$QF?H"X_&,_; ?T W>$W.T,^$$8$S+GY
MWS#=J"W\*J%$H"E?/U.2$5E0[/@,?3SX?HG&XP'5?B,LYN+K_:RJ]C'+GM.S
MR>3U]?6 \1?\RL53>A#Q]; *YQG.-FE5V^'VL/Q3A'^B"7LZ4W\M<4J0/%PL
M/=NFR?E([;?<[>O) 1>KR?'AX='DG[]>SZ-'LL;CA*G#%I&1CE*UV.*.3D]/
M)WFIEK:4VZ6@>A\G$VVGJEF6)AWZFI,T.4MS>]<\PEG>Z[V[0:!"_6^L96.U
M:7QT/#XY.MBF\4@?_/P("D[)/7E >3//LMVS)"E-% BC
$CI!22C[ =ITVZBJ#)J[-WA&1\/B2O<^U
M&>W)OOSNB.Q_:$ ]WGD3%CS#]%WFZY'.;=^0]QWQ?9S[(RV'>?*^(UV+_+_8
MSMJ6WWQX[<>5JHW7\E/#(MEF<@(CL3:IJN@8@?,]Y!-#67=5.X\:]5(UFG/1
M;KN:&?,Z4Q(=K/C+)":)K/OXH_HP5A_R9LO__#GE
DY&]/B,!;A#X*OK;LM6\TMA7_2915?'!:Y
M"\!H0R9(RC
>+H@K$-IO?DF8LN?)HRU]383)JPU#5!,6(Q!J)1:%$A]D3$;QMYQDX$
MW?5"T5*ZY@*P:J)AR(*BP^X-!*22^V5D(3!+$S6 ]4+2ECH_W0#,MDX]#%U0
MG #FX%.22N^7E/DCH53=#L"L?T"QB5W3 ALV>6DK@R(&M
@,B0<;"Y?
MU.I<+I,&-K:F]PE/RW87/Y4X6(1,AP,IRL.0BO-$4NTV1 ]#+:5K>@"K)C>&
M+"AB[-Y 5@HYRO7^(;ED\2!$*IT?0 R;=CQ*48!P-)WUH2'5/L&X2M((T\++
ME=R6=C3/HG4-"&C7A*0E# H4R!T(2Q&@F
NO#1.F]0#+="-%P#<\XL-393=D>L]7]64 7!"@]YEIW;0MY Q1/,] E
MRY)LIQZGN]FLET18&M>6N&(#,J>9,,N#8 $P93)0R)#2H4+HI>?U70*6J8<8
MP>:8,K<$V$TV*6AJ B+!:@R@8:_-GRGU0L14CDP"TQF+R?87L@/;U=*Y90*P
MV83"$ 5$A=T9@$4I1KD:2;D7,.Y$LL9B-T^BGJFB+72+!F2TR8:I"@@.P!I
M1ZE&\]G4YTRRP-M9+$%-'I+B>? >2D"]6UAZ;#>9 <0!H=/M$"!(!J%FE$^0
M9BSBXIG7'G>8\HT< '=3'L,KE)XHMU -:D(3K
5(U>"'N(H[E@4K+?ZX31H[ ]ENU;NGJL-MDRB(,B"38'
ZU@SE1]OQ8*_VA[.!I5>D&E;M0*SEX6'2\M;'RPJ0*UG5(A/3/*%U:VX
M$_PE81&\9(;D7H !3%NI,;3AH6,WV,=/M2#6<5['FF)1WOLET3(_HTS3I'V(
M*33A0=(TUCNX%&J?2-SQ-,/TW\ESYXFX7>P%#ZMA*R0-97BHV.SU 5/$(!GD
MX\2ZQ%7=T+"^2F:4NWL%V&)K_PIPK3 ("&R.VJ\ %U=/"I'K;E:,"H*!$:%9
M[*R3+::J/JZ5A='%;4.M'LZ_UU+CXXNLLKO0NT?.X <$VA)7/0V9T[UME@?1
MXX IL]=S&
_-WD61R
MSU.^7F]8>9?']MP@H'/5RYTV=8];14'T?I
0*"-B@IJ&M" (%T);)P5Z(M-(Q!'>"* B)[(C\)4"56$C!(\EQ!-"H'D
MI)8^1)P@D[U0%8$^V9J3:"/GQ]W1\7*19-1V
GZQSO=_)3]86@GHG.6T[+)9);6TB8)@I,M9*ZUED72N)D9*[9J+
M39QD)"[,7"4,LRC!M$J/:+LBWA_BC):!YBMP>O1A,#3,9 NG(DSG,JP"]ZDN
M75]*+Q[ ^)U0^@OCKVQ.<,H9B8MK*;8[1=UZMT_,]-AN/C0#B(/ :8A#X-$9
M%31^4E%(AY57PKR0](W3#
PV23&$ 5$BMT90$@E1H7:
MSPO:1?:(:I%5_.X0V$!([OAU[4[3QEO;5FU S'0:A-[A+G-^[-?&192G5RPS
MHGXO(GDA7W"&2V]@>R&YZY
T9R?+V@H (:+N"4N3E0I0KO?3_9\R>Q.8Y
MBW9W@D>$J*>LTFJTZKO^-C#:+3-O:E*3ID&A 7'V%K\ @?LJ4*V.#[49R^?%
M//70N,KFQJ.G^2.6!_!VDZ5J!I7&X*O@G4&.;R\,:(!QDZ$C(B#T!MB$;CCD
MD2@/_8"*8%2+]G1^ENZS )+X\^Z>/!"AWCM8D&WV6>[HJ>,,8T"LZ[.WP
?7Q/I)E'TORY<=5S(,7JC23XJK1/CEM
M!%2$,F)B=M7X-FI>CWJ#02/0"1$1X5+0JX:0C8]__?I+8'XN?VLV@SZC/.H&
MGV38'(BI_!#
?)+SL1SU_Z:$$T#@TOH[DJSJX8M=U/L\NQ$JEFK
_-N&H:GLSD2RNBK&49V \9C R$^>='5M#U1">*
MA$F1$R<3RK/\?QC-@:150ZT*$F.38WFE]A6'==IMK&L5!E)%5!G615Y$A7M-
M=-P1-XK6@BB343.<,[YMW:F2L8O.AH1T5'07E"FB'IK7IOS(UJ'/R:P
TH@WPXJWQ)O-6,NSIU'.F.VOK8J]O)*[4'_
MN.!( @1_ACE2>-TBM<"U$"GACW0A507X?260]Q^8O,N\(6'^.R4JH8JO(:2/
MQ$#8[S!A.QPB\1XK(C2S?"# C]5 XN>H-QX.CTC(1W/*N8W8B #U\C(]$/N?
MF-C=/M\ ^-L7>WTWEQ8X^YTD0/SOWPK^([=(+?! %9.1N:0K /LC,9#Z!29U
MAT-4WK
2L'Q#S[L WM(J/M,AX3G->J;8]J/NT0.18X2
"]5:J\RWE'%K88B1PE JTS6S/Q6)"Q9VT?\]VD\^?G@
M=)_UL0K*&"7H=)E"85L\:1")G;KP\3U40AFCQ)H^
\:/(GP@(KKZ0M<^
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MVYW)V.Z8<8PR1RHH:Y20SV6J9K;W
.?:B
M1'PN4TAL\[7AYHP:3CB;$?=.,F\"\#X;3.(>JW7OW\NV_-A=VRK.ZM$W'\JQ
M.Z10X#A;)'WVZD:=1BRA45ZE/A-$A":DVNYK
&;2/V=^((321EP*6VH-!?(H)IS?I)H)JKUCRX$0"AEQ
MS6NI-13(MS%5,S.H?59RF
SM]L!T)H- 15[9ZK>+ 7_W<1Y[O?_.2+U&#
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M% ,4 " #&8QM=_3")4QX? >K0 #0 @ $ =F%L
M:6]N7SAK+FAT;5!+ 0(4 Q0 ( ,9C&UW]:8BG/P4 -(7 1
M " 4D? !V86QI;VY?97@P,S Q+FAT;5!+ 0(4 Q0 ( ,9C&UU+
MK021F0\ " ^ 1 " ;
&UL4$L%!@ & 8 ?@$ (1* $!
end
XML
16
valion_8k_htm.xml
IDEA: XBRL DOCUMENT
0001787740
2026-08-26
2026-08-26
false
--12-31
0001787740
8-K
2026-08-26
Valion Bio, Inc.
DE
001-41052
81-4016391
1305 E. Houston Street,
San Antonio
TX
78205
888
276-6888
false
false
false
false
Common Stock, par value $0.0001 per share
VBIO
NASDAQ
true
false